Solventum’s (SOLV) Hold (C) Rating Reiterated at Weiss Ratings

Weiss Ratings reaffirmed their hold (c) rating on shares of Solventum (NYSE:SOLV) in a research report sent to investors on Thursday,Weiss Ratings reports.

Several other equities analysts have also recently issued reports on the company. Morgan Stanley upgraded Solventum from an “equal weight” rating to an “overweight” rating and boosted their target price for the stock from $80.00 to $103.00 in a research report on Tuesday, July 15th. Wells Fargo & Company upped their price target on Solventum from $79.00 to $82.00 and gave the stock an “equal weight” rating in a report on Monday, September 15th. Jefferies Financial Group assumed coverage on Solventum in a report on Thursday, September 11th. They issued a “hold” rating and a $80.00 price target on the stock. Zacks Research upgraded Solventum from a “hold” rating to a “strong-buy” rating in a report on Monday, September 15th. Finally, Wall Street Zen cut Solventum from a “strong-buy” rating to a “buy” rating in a report on Tuesday, September 9th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, seven have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Solventum currently has a consensus rating of “Hold” and an average price target of $84.89.

Solventum Stock Performance

NYSE SOLV opened at $69.04 on Thursday. The company has a current ratio of 1.22, a quick ratio of 0.86 and a debt-to-equity ratio of 2.14. The business’s 50 day moving average is $72.41 and its two-hundred day moving average is $72.33. Solventum has a 12-month low of $60.70 and a 12-month high of $85.92. The stock has a market capitalization of $11.97 billion, a price-to-earnings ratio of 31.96, a PEG ratio of 2.80 and a beta of 0.50.

Solventum (NYSE:SOLV) last released its earnings results on Thursday, August 7th. The company reported $1.69 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.45 by $0.24. Solventum had a return on equity of 29.93% and a net margin of 4.52%.The company had revenue of $2.16 billion for the quarter, compared to analysts’ expectations of $2.12 billion. During the same quarter in the previous year, the firm posted $1.56 EPS. The firm’s quarterly revenue was up 3.8% on a year-over-year basis. Solventum has set its FY 2025 guidance at 5.800-5.950 EPS. Research analysts expect that Solventum will post 6.58 EPS for the current year.

Institutional Investors Weigh In On Solventum

A number of large investors have recently bought and sold shares of SOLV. Independent Franchise Partners LLP grew its holdings in Solventum by 74.2% during the 2nd quarter. Independent Franchise Partners LLP now owns 10,141,066 shares of the company’s stock valued at $769,098,000 after buying an additional 4,320,342 shares during the last quarter. Norges Bank acquired a new stake in Solventum during the 2nd quarter valued at $140,495,000. Boston Partners grew its holdings in Solventum by 101.3% during the 1st quarter. Boston Partners now owns 3,361,973 shares of the company’s stock valued at $255,554,000 after buying an additional 1,691,565 shares during the last quarter. Nuveen LLC acquired a new stake in Solventum during the 1st quarter valued at $35,375,000. Finally, Assenagon Asset Management S.A. grew its holdings in Solventum by 60.3% during the 3rd quarter. Assenagon Asset Management S.A. now owns 928,830 shares of the company’s stock valued at $67,805,000 after buying an additional 349,463 shares during the last quarter.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.